The purpose of this study was to evaluate the efficacy and safety of onabotulinumtoxin A and Chinese botulinum toxin type A (CBA) for masseter reduction using elastography and electromyographic measurement. Female subjects aged 21 to 38 years with benign masseter hypertrophy received 1 treatment of either 50 units onabotulinumtoxin A or 50 units CBA in a double-blind clinical trial. The study enrolled 102 subjects (204 sides of masseters); 51 subjects per group. The thickness and stiffness of the masseter muscle and the electromyographic changes were evaluated before and 1, 4, 12, and 24 weeks after injection. One week after injection, the thickness of the masseter muscle did not change significantly, but the stiffness was reduced by 5% to 9%. After 4 weeks of injection, masseter muscle thickness, stiffness and strength decreased significantly compared with before injection. The changes were significantly at 12 weeks. Muscle stiffness measured by Shear-wave elastography was significantly reduced by 20% to 32% in the relaxed state and 25% to 47% in the contractile state. The electromyography showed that masseter muscle strength changed consistently with Shear-wave elastography value before and after injection. Six months after injection, ultrasound and electromyography showed that the masseter muscle thickness and stiffness began to recover. Between the 2 groups, there are no significant difference in thickness, stiffness and muscle strength reduction of masseters after treatment ( P > 0.05), as well as in side effects ( P > 0.05). Onabotulinumtoxin A and CBA were comparable in the efficacy and safety for masseter reduction.
Copyright © 2022 by Mutaz B. Habal, MD.